Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Dillon

Showing results (131-140 of 176) with videos related to

Pageof 18
Sort By:
Alimentary Pharmacology & Therapeutics|June 4, 2019
Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage studyScott A McDonald, Stephen T Barclay, Sharon J Hutchinson, et al.
Journal of Viral Hepatitis|September 1, 2025
Risk Factors for Hepatitis C Virus Among the General Population in Sub-Saharan Africa-An Analysis of Systematic Review DataGetahun Molla Kassa, Aaron G Lim, Melaku Tileku Tamiru, et al.
Journal of Viral Hepatitis|November 8, 2019
Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosisScott A McDonald, Kevin G Pollock, Stephen T Barclay, et al.
BMJ Open Gastroenterology|January 7, 2022
Effect of COVID-19 on presentations of decompensated liver disease in ScotlandThomas Manship, Paul N Brennan, Iona Campbell, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 8, 2016
The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-αJames G Orr, Craig J Currie, Ellen Berni, et al.
Lancet (London, England)|December 22, 2022
Deaths from alcohol-related liver disease in the UK: an escalating tragedyMichael E D Allison, Julia Verne, William Bernal, et al.
Frontline Gastroenterology|October 26, 2017
The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)Mark Hudson, Amr Radwan, Paola Di Maggio, et al.
Cellular and Molecular Gastroenterology and Hepatology|March 20, 2018
Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2)Ritu S Sharma, David J Harrison, Dorothy Kisielewski, et al.
Hepatology (Baltimore, Md.)|November 3, 2011
Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from careHamish A Innes, Sharon J Hutchinson, Samuel Allen, et al.
European Journal of Gastroenterology & Hepatology|March 22, 2012
Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in ScotlandHamish A Innes, Sharon J Hutchinson, Samuel Allen, et al.
Pageof 18

Showing results (131-140 of 176) with videos related to

Sort By:
Pageof 18
Alimentary Pharmacology & Therapeutics|June 4, 2019
Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage studyScott A McDonald, Stephen T Barclay, Sharon J Hutchinson, et al.
Journal of Viral Hepatitis|September 1, 2025
Risk Factors for Hepatitis C Virus Among the General Population in Sub-Saharan Africa-An Analysis of Systematic Review DataGetahun Molla Kassa, Aaron G Lim, Melaku Tileku Tamiru, et al.
Journal of Viral Hepatitis|November 8, 2019
Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosisScott A McDonald, Kevin G Pollock, Stephen T Barclay, et al.
BMJ Open Gastroenterology|January 7, 2022
Effect of COVID-19 on presentations of decompensated liver disease in ScotlandThomas Manship, Paul N Brennan, Iona Campbell, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 8, 2016
The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-αJames G Orr, Craig J Currie, Ellen Berni, et al.
Lancet (London, England)|December 22, 2022
Deaths from alcohol-related liver disease in the UK: an escalating tragedyMichael E D Allison, Julia Verne, William Bernal, et al.
Frontline Gastroenterology|October 26, 2017
The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)Mark Hudson, Amr Radwan, Paola Di Maggio, et al.
Cellular and Molecular Gastroenterology and Hepatology|March 20, 2018
Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2)Ritu S Sharma, David J Harrison, Dorothy Kisielewski, et al.
Hepatology (Baltimore, Md.)|November 3, 2011
Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from careHamish A Innes, Sharon J Hutchinson, Samuel Allen, et al.
European Journal of Gastroenterology & Hepatology|March 22, 2012
Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in ScotlandHamish A Innes, Sharon J Hutchinson, Samuel Allen, et al.
Pageof 18